Ventyx Biosciences shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $12 price target. Also, Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $7 to $16.
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences' stock price is on the rise following upgrades from Oppenheimer and Wells Fargo. Oppenheimer upgraded Ventyx from Perform to Outperform with a $12 price target, while Wells Fargo moved its rating from Equal-Weight to Overweight and set a new price target of $16, up from $7.
March 12, 2024 | 11:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ventyx Biosciences sees a significant positive impact on its stock price following upgrades by Oppenheimer and Wells Fargo, with new price targets set at $12 and $16 respectively.
The upgrades from two reputable financial institutions, Oppenheimer and Wells Fargo, signal a strong vote of confidence in Ventyx Biosciences. The significant increase in price targets suggests a positive outlook on the company's future performance, likely leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100